AR125450A1 - ANTI-ADGRE2 ANTIBODIES AND USES THEREOF - Google Patents
ANTI-ADGRE2 ANTIBODIES AND USES THEREOFInfo
- Publication number
- AR125450A1 AR125450A1 ARP220101068A ARP220101068A AR125450A1 AR 125450 A1 AR125450 A1 AR 125450A1 AR P220101068 A ARP220101068 A AR P220101068A AR P220101068 A ARP220101068 A AR P220101068A AR 125450 A1 AR125450 A1 AR 125450A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- adgre2
- fragments
- fusion proteins
- cancers
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen anticuerpos, fragmentos de los mismos y proteínas de fusión que se unen específicamente a ADGRE2, así como métodos preparación y uso de tales anticuerpos. Estos anticuerpos, proteínas de fusión y fragmentos de los mismos son de utilidad para el tratamiento y el diagnóstico de diversas enfermedades autoinmunes y cánceres, incluyendo, por ejemplo, leucemia mieloide aguda.Antibodies, fragments thereof, and fusion proteins that specifically bind to ADGRE2 are described, as well as methods of making and using such antibodies. These antibodies, fusion proteins, and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including, for example, acute myeloid leukemia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163179756P | 2021-04-26 | 2021-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125450A1 true AR125450A1 (en) | 2023-07-19 |
Family
ID=81648880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101068A AR125450A1 (en) | 2021-04-26 | 2022-04-25 | ANTI-ADGRE2 ANTIBODIES AND USES THEREOF |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230018888A1 (en) |
EP (1) | EP4330283A1 (en) |
JP (1) | JP2024518776A (en) |
KR (1) | KR20240004287A (en) |
CN (1) | CN117580860A (en) |
AR (1) | AR125450A1 (en) |
AU (1) | AU2022266583A1 (en) |
BR (1) | BR112023020371A2 (en) |
CA (1) | CA3214355A1 (en) |
CL (1) | CL2023003174A1 (en) |
CO (1) | CO2023013195A2 (en) |
EC (1) | ECSP23088752A (en) |
IL (1) | IL307940A (en) |
MX (1) | MX2023011712A (en) |
TW (1) | TW202305003A (en) |
WO (1) | WO2022232035A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024089622A1 (en) * | 2022-10-25 | 2024-05-02 | Takeda Pharmaceutical Company Limited | Adgre2 chimeric receptor nk cell compositions and methods of use |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2703893B2 (en) | 1985-07-05 | 1998-01-26 | ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ | Epithelial cells expressing foreign genetic material |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
JP2914692B2 (en) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | Endothelial cell genetic modification |
WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JP3249516B2 (en) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | Retroviral vectors for gene therapy |
JPH07503124A (en) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | Antibody fragments and their complexes produced by microorganisms |
JP4157160B2 (en) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | Methods for the preparation of modified antibody variable regions |
SE9201984D0 (en) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | IMPROVEMENT IN OPTICAL ASSAYS |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
AU7467898A (en) | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
PE20011227A1 (en) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES |
US6719750B2 (en) | 2000-08-30 | 2004-04-13 | The Johns Hopkins University | Devices for intraocular drug delivery |
DK1355919T3 (en) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molecules with longer half-lives, compositions and uses thereof |
CN100349629C (en) | 2001-09-12 | 2007-11-21 | 贝克顿迪肯森公司 | Microneedle-based pen device for drug delivery and method for using same |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
FR2849436B1 (en) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | PARTICLES AND CERAMICS OF CALCIUM PHOSPHATES FOR TRANSFECTION IN VIVO AND IN VITRO |
WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
CA2693771A1 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
EP2545079A2 (en) | 2010-03-11 | 2013-01-16 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
EP2622074B1 (en) | 2010-09-30 | 2014-11-12 | Board Of Trustees Of Northern Illinois University | Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents |
JP6296536B2 (en) * | 2010-11-05 | 2018-03-20 | メドベット サイエンス ピーティーワイエルティーディーMedvet Science Pty Ltd | Endothelial progenitor cell markers and uses thereof |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
MA43282A (en) * | 2015-11-19 | 2018-09-26 | Abbvie Stemcentrx Llc | NEW ANTI-EMR2 ANTIBODIES AND RELATED METHODS OF USE |
CA3000514A1 (en) * | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
-
2022
- 2022-04-25 WO PCT/US2022/026161 patent/WO2022232035A1/en active Application Filing
- 2022-04-25 BR BR112023020371A patent/BR112023020371A2/en unknown
- 2022-04-25 KR KR1020237034369A patent/KR20240004287A/en unknown
- 2022-04-25 US US17/728,598 patent/US20230018888A1/en active Pending
- 2022-04-25 CN CN202280030498.9A patent/CN117580860A/en active Pending
- 2022-04-25 EP EP22723302.0A patent/EP4330283A1/en active Pending
- 2022-04-25 JP JP2023565453A patent/JP2024518776A/en active Pending
- 2022-04-25 MX MX2023011712A patent/MX2023011712A/en unknown
- 2022-04-25 CA CA3214355A patent/CA3214355A1/en active Pending
- 2022-04-25 IL IL307940A patent/IL307940A/en unknown
- 2022-04-25 TW TW111115646A patent/TW202305003A/en unknown
- 2022-04-25 AU AU2022266583A patent/AU2022266583A1/en active Pending
- 2022-04-25 AR ARP220101068A patent/AR125450A1/en unknown
-
2023
- 2023-10-03 CO CONC2023/0013195A patent/CO2023013195A2/en unknown
- 2023-10-24 CL CL2023003174A patent/CL2023003174A1/en unknown
- 2023-11-23 EC ECSENADI202388752A patent/ECSP23088752A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023011712A (en) | 2023-10-12 |
ECSP23088752A (en) | 2024-01-31 |
CO2023013195A2 (en) | 2023-10-19 |
IL307940A (en) | 2023-12-01 |
CL2023003174A1 (en) | 2024-05-24 |
EP4330283A1 (en) | 2024-03-06 |
WO2022232035A1 (en) | 2022-11-03 |
CA3214355A1 (en) | 2022-11-03 |
AU2022266583A9 (en) | 2023-10-26 |
AU2022266583A1 (en) | 2023-10-19 |
KR20240004287A (en) | 2024-01-11 |
CN117580860A (en) | 2024-02-20 |
JP2024518776A (en) | 2024-05-02 |
TW202305003A (en) | 2023-02-01 |
BR112023020371A2 (en) | 2024-02-06 |
US20230018888A1 (en) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019013611A2 (en) | Specific antibodies for flt3 and their uses | |
ECSP20082991A (en) | BINDING AGENTS OF PSMA AND USES OF THEM | |
CL2020003028A1 (en) | Anti-cd33 antibodies, anti-cd33 / anti-cd3 bispecific antibodies and their uses. | |
UY37698A (en) | PROTEINS OF UNION TO TREM2 ANTIGENS AND USES OF THESE | |
CO2020000214A2 (en) | Agonist antibodies that bind to human cd137 and their uses | |
CO2017005240A2 (en) | Cd3 / cd38 t-cell redirection hetero-dimer immunoglobulins and their production methods | |
ECSP23088752A (en) | ANTI-ADGRE2 ANTIBODIES AND USES THEREOF | |
CL2019003520A1 (en) | Antibodies that specifically bind to pd-1 and procedures for use. | |
PE20220142A1 (en) | HEAVY CHAIN ANTIBODIES THAT BIND TO PSMA | |
CR20170059A (en) | ANTIBODIES Anti-LAG3 AND FRAGMENTS OF UNION TO ANTIGEN | |
ECSP18096095A (en) | ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM | |
UY37591A (en) | ANTIBODY DRUG CONJUGATES | |
PE20210110A1 (en) | MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF USE | |
CR20120086A (en) | HIGH AFFINITY HUMAN ANTIBODIES FOR HUMAN ANGIOPOYETINA-2 | |
CL2020000576A1 (en) | Antibodies to programmed cell death protein 1 | |
UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
CO2020005347A2 (en) | CD123 Specific Antibodies and Antibody-Drug Conjugates and Uses Thereof | |
EA202092302A1 (en) | ANTIBODIES TO TREM-1 AND THEIR APPLICATIONS | |
UY36706A (en) | ANTIBODIES DIRECTED TO THE BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS FROM THESE | |
CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
AR113223A1 (en) | MONOCLONAL ANTIBODY FOR PD-L1 | |
ECSP20039728A (en) | MONOCLONAL ANTIBODIES AND METHODS TO USE THEM | |
PE20201149A1 (en) | HLA-A2 / WT1 BINDING ANTIBODIES | |
CO2024004055A2 (en) | Polypeptides | |
CO2023014316A2 (en) | Anti-clec12a antibodies and their uses |